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the public debate, not as a
genuine search for the public
view, but as a way of getting
greater acceptance,” he wrote.
“Now they are hoist with their own
petard. The people who registered
their views were more hostile than
the public at large.”
The figures were drawn from
over 600 public meetings
throughout the country — which,
as The Independent pointed out,
were not designed to achieve a
cross-sample of the population at
large. “Indeed, there is a case for
saying that there is a ‘self-
selecting’ effect at work in such a
consultation exercise, because
those most likely to turn up to
such a meeting might be
expected to be those most
passionately opposed to GM
products.”
The Times insisted that the
results had particular force
because they did not come solely
from meetings packed with
opponents. “The findings were
confirmed by 77 people who were
selected randomly as
representative of the general
public, a grouping named
‘Narrow-But-Deep’. The panel
was less dogmatic in its
opposition to GM but wished the
government to delay a decision
until there were more tests.”
A third surprise was the
response of The Guardian, which
in 1999 highlighted Arpad
Pusztai’s claims about alleged
dangers of GM crops, and whose
editor co-authored the anti-GM
television drama Fields of Gold
last year. Though it carried two
articles on the survey results, The
Guardian devoted as much space
to a piece warning that “public
antipathy toward GM crops is
driving Britain’s leading plant
scientists to seek greener
pastures abroad”.
Prominent among researchers
quoted was Richard Flavell,
formerly of the John Innes Centre
in Norwich and now with Ceres in
California. “The situation is more
disturbing in the UK than
anywhere else in the world,”
Flavell was quoted as saying.
“The untruths, lies and lack of
orchestrated information make it
impossible for the average person
to make an informed decision.” So
“GM Nation?” (who on earth
decided to call it that?) did not
spawn a uniform, hysterical
chorus from the media. True, most
journalists and editors decided to
amplify its negative verdicts. But a
significant minority urged caution.
Of these, The Times struck
arguably the most appropriate
note. Citing both “scaremongering
about health effects” and
“genuine scientific uncertainty
about environmental effects”, it
concluded that the British people
“do not want to close the door,
but have questions that need
answers”.
Bernard Dixon is the European editor
for the American Society of
Microbiology.
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If you have billions of dollars to
spend on good causes, the
choices can be hard. Which
diseases can be eradicated, how
many lives can be saved from
misery and untimely death?
Should I address the acute
problems first, or think long-term
and tackle the chronic issues?
Microsoft founder Bill Gates, who
has pledged to return his
immense fortune to society before
he dies, is facing these kinds of
questions now. And it appears
that he has found some sensible
answers.
The Bill and Melinda Gates Foun-
dation (www.gatesfoundation.org)
currently weighs in at 25 billion US
dollars, that is more than twice the
value of the Wellcome Trust, one of
the world’s largest charitable
foundations for the support of
biomedical research in the UK and
elsewhere. The foundation is based
at Seattle and led by Bill Gates’
father, William H. Gates, Sr., and
former Microsoft manager Patty
Stonesifer. Originally, the founda-
tion was focused mainly on educa-
tion, but when Gates discovered
the catastrophic state of world
health from reading the 1993
edition of the World Bank’s World
Development Report, he swiftly
decided to throw his money at the
most urgent problems in this field.
And the most urgent problems
tend to be located in sub-saharan
Africa, where the double
onslaught of AIDS and of the
traditional tropical diseases
including malaria costs many
millions of lives every year. Some
of the first funding initiatives of the
Gates foundation in Africa are
already bearing fruit. One is
addressing the AIDS problem in
Botswana, the other is a major
immunization initiative which has
already delivered vaccines to
millions of children.
Their next target is malaria, and
it is a worthwhile target if ever
there was one. Although attempts
to control malaria have been
made over many decades, and
there are programmes to support
research from many bodies
including the WHO, mortality from
this disease is currently
increasing, as resistance genes
against the common drugs spread
among the populations of the
deadliest malaria parasite,
Plasmodium falciparum, and there
is a shortage of new drugs.
Further contributing factors
include insecticide resistance in
the Anopheles mosquitoes which
carry the parasite, and wars
leading to diseases spreading
among refugee populations. While
Africans who survive into
adulthood tend to have acquired a
certain degree of immunity, the
mortality is highest among young
children and pregnant women. All
this adds up to over one million
deaths per year, and crippling
costs to the African economies.
All recent initiatives have failed to
‘roll back malaria’, as one program
was enthusiastically entitled, or
even dent its progress, mainly
because they were drastically
under-funded.
On their recent visit to
Mozambique, the Gateses
announced a $168 million funding
initiative to tackle malaria. To put
the number into perspective, this
is about the same order of
magnitude as the global annual
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spend on malaria prevention in
recent years. And yet, it is an
order of magnitude smaller than
the experts’ estimate of the
annual budget that would be
needed to wipe out the disease
for good. So where is the money
going? It splits up into three
major grants for different
measures:
•New prevention strategies
using existing drugs. An approach
known as the ‘intermittent
preventive treatment in infants’
(IPTI) involves giving children anti-
malarial drugs three times during
their first year. Recent studies
have shown that this approach,
carried out with affordable drugs,
can reduce the incidence of the
disease, and of its deadliest form
in particular, by half. $28 million
are earmarked for a five-year
research project to develop this
treatment further.
This adds up to one million
deaths per year, and
crippling costs to the
African economies. All
recent initiatives have
failed to ‘roll back malaria’,
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mainly because they were
drastically under-funded
•New anti-malaria drugs.
Another five-year grant of $40
million goes to the Medicines for
Malaria Venture (MMV), a
public–private partnership based
in Switzerland. MMV has more
than 20 potential drugs in the
development pipeline, including
four advanced candidates that are
already considered as extremely
promising, and aims at making at
least one new anti-malaria drug
widely available by the end of this
decade.
•Vaccines. The biggest piece of
the cake, worth $100 million, will
go to the Seattle-based Malaria
Vaccine Initiative (MVI), which has
a portfolio of 15 vaccine
candidates.
With the two biggest grants
funding organisations based in
rich countries, one may be
forgiven for thinking that the
money ultimately ends up in the
pockets of Swiss or American
researchers, for whom malaria is
just a job, not a question of life
and death. Shouldn’t the
developing countries get the
chance to be more involved in this
research? So far, the laboratory of
controversial Colombian
researcher Manuel Elkin Patarroyo
is about the only one in the
developing world that managed to
get noticed.
Bill and Melinda Gates have
already acknowledged the need
for more African involvement, as
they demonstrate by the planning
of their recent trip to the
Mozambique. This country is
among those that are most
affected by malaria, but it is also
making increasing contributions
to global malaria research. The
research center at Manhiça,
where the Gateses met doctors,
patients, and leading Mozambican
politicians to announce the new
funding spree, is already a focus
of malaria research in the
suffering continent, and it is
currently conducting a phase II
clinical trial of a potential malaria
vaccine.
Bill Gates earned himself the
applause of those who care about
the misery in the developing world
not only by his generosity, but
also by his increasingly outspoken
comments. “It’s time to treat
Africa’s malaria epidemic like the
crisis that it is,” he said in
Mozambique. “It is unacceptable
that 3,000 African children die
every day from a largely
preventable and treatable
disease.” Privately, he may
already have reached the point of
realising that this crisis would not
have been allowed to reach its
current status if those 3,000
children per day were white.
The media response to Gates’
funding announcement was
overwhelmingly positive, with
praise being handed out not only
by the general press but also by
scientific titles such as Nature. In
an amazingly rapid shift of
perception, the “devil” who
swamped the world with his IT
monopolies is now turning into
“Saint Bill”. It’s not all bad being a
billionaire, as long as you know
what to do with the billions.
Michael Gross is a science writer in
residence at the school of
crystallography, Birkbeck College,
London. He can be contacted via his
web page at
www.proseandpassion.com.
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Lethal injection: Millions of young Africans die contracting malaria as a result of
infection from the bite of a mosquito. The Bill and Melinda Gates Foundation is
putting new money into tackling this disease. (Picture: Science Photo Library.)
